Unclaimed profileSeeded from SAM.gov and USAspending public records

Claim this profile Capability statement (.md)

PROGENICS PHARMACEUTICALS INC

BEDFORD, MA 01730-1452
Corporate Entity (Not Tax Exempt)

UEIYLYKVRPCTCR3CAGE34KE9NAICS325412

SAM expiring
No verified credentials yet
CMMCNot on file
SPRSNone
FCLVisible to paid members

Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works

36-mo obligations: $0
Awards on record: 0
Contract vehicles: 0
Verified credentials: 0

SAM.gov registration expires in 56 days

PROGENICS PHARMACEUTICALS INC’s registration expires on Jan 8, 2027. Renewal can take weeks; confirm it stays active through proposal submission and award.

View on SAM.gov (opens in a new tab)Learn more about SAM registration and the UEI

About PROGENICS PHARMACEUTICALS INC

PROGENICS PHARMACEUTICALS INC is a SAM.gov-registered entity based in BEDFORD, MA 01730-1452. UEI YLYKVRPCTCR3; CAGE 34KE9; primary NAICS 325412. Compliance posture not provided. SAM registration expires in 56 days.

Headquarters: BEDFORD, MA 01730-1452

Identifiers

UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.

UEIYLYKVRPCTCR3
CAGE34KE9

Capabilities & differentiators

No capability narrative yet

The company has not published a capability narrative. Its SAM.gov registration, NAICS codes and award history are below.

Is this your company? Claim it

Compliance posture

Every credential shows who vouches for it: verified by TeamingIndex, or self-attested by the contractor.

No compliance posture published yet

Compliance facts appear once the company claims this profile and publishes them.

Is this your company? Claim it

Facility clearance

Facility clearance: visible to paid members

Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans

Past performance

Recompete Radar Learn more

No federal prime awards on record

USAspending shows no prime awards for this UEI in the last 36 months. Subcontract work does not appear here.

Claim this profile

Contract vehicles

Learn more

No contract vehicles on file

This company has not listed GWAC, IDIQ, GSA Schedule or OTA consortium holdings.

Browse vehicle holders

Proven teaming graph

Learn more

Who PROGENICS PHARMACEUTICALS INC has actually worked with, from sub-awards that prime contractors report to the government. Use it to see which primes already trust this company.

No sub-award reports yet

Prime contractors report first-tier subcontracts of $30,000 or more. None name this company yet, which is common for companies that mostly win prime contracts or work below the reporting threshold.

See where agencies spend

Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.

SBIR/STTR portfolio

Learn more About SBIR/STTR

Small Business Innovation Research and Technology Transfer awards: early-stage federal R&D money this company has won.

SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects

Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.

Awards on record: 44 awards
Total awarded: $32,833,406
By phase: SBIR Phase I: 31
SBIR Phase II: 13
By agency: Department of Health and Human Services: 44
By year: 2007: 4
2006: 2
2005: 1
2004: 5
2003: 6
2002: 8
2001: 3
2000: 2
1999: 3
1997: 1
1996: 2
1995: 1
1994: 2
1993: 1
1992: 1
1991: 1
1990: 1

Awards (most recent first)

Broadly Neutralizing MAbs against Hepatitis C Virus
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2007 · $351,433
Solicitation year 2007
Novel small-molecule inhibitors of HIV-1 Vif
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2007 · $291,281
Solicitation year 2007
PSMA-VRP vaccine for prostate cancer
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2007 · $428,780
Solicitation year 2007
PSMA Antibody-Drug Conjugate for Prostate Cancer Therapy
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2007 · $473,537
Solicitation year 2007
Broadly Inhibitory MAbs Targeting Hepatitis C Virus Receptors
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2006 · $620,713
Solicitation PHS2006-2 (2006)
Developement of an alphavirus vaccine for melanoma
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2006 · $614,996
Solicitation PHS2006-2 (2006)
Development of Hepatitis C Virus Inhibitors
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2005 · $3,029,040
Solicitation PHS2005-2 (2005)
CCR5 inhibitors that block HIV but not chemokines
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2004 · $617,186
Solicitation PHS2004-2 (2004)
PRO 542 Immunotherapy of Advanced HIV 1 Disease
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2004 · $591,376
Solicitation PHS2004-2 (2004)
PSMA-Targeted Immunotoxins for Prostate Cancer Therapy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2004 · $550,179
Solicitation PHS2004-2 (2004)
Development of PSMA -based recombinant protein vaccines
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2004 · $3,635,260
Solicitation PHS2004-2 (2004)
Human PSMA MAb Radioimmunotherapy for Prostate Cancer
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2004 · $3,830,890
Solicitation PHS2004-2 (2004)
Novel Human Anti-CD19 Antibodies for Lymphoma Therapy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2003 · $525,950
PSMA-KLH Conjugate Vaccines for Prostate Cancer
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2003 · $520,839
Humanized PRO 140 for CCR5-Targeted Therapy of HIV
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2003 · $3,036,480
Humanized PRO 140 for CCR5-Targeted Therapy of HIV
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2003 · $0
Development of Small-Molecule HIV Entry Inhibitors
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2003 · $0
Development of Small-Molecule HIV Entry Inhibitors
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2003 · $2,707,682
NOVEL INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2002 · $600,638
DEVELOPMENT OF HEPATITIS C VIRUS ENTRY INHIBITORS
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2002 · $594,489
DEVELOPMENT OF PSMA-BASED VACCINES FOR PROSTATE CANCER
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2002 · $100,000
DEVELOPMENT OF ANTI-PSMA ANTIBODIES FOR PROSTATE CANCER
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2002 · $196,950
ALPHAVIRUS PRIME-BOOST VACCINES FOR PROSTATE CANCER
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2002 · $366,535
HUMAN ANTI-PSMA ANTIBODIES FOR PROSTATE CANCER THERAPY
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2002 · $371,046
TRANSGENIC PRODUCTION OF CD4-IGG2 FOR HIV THERAPY
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2002 · $2,640,409

Showing the 25 most recent of 44 awards.

Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026

FedRAMP offerings

Learn more

Cloud services this company lists on the FedRAMP Marketplace, the government's record of cloud authorizations.

No FedRAMP Marketplace listing

No FedRAMP Marketplace listing is linked to this company. Cloud providers appear here automatically once FedRAMP lists their offering.

Find FedRAMP-authorized companies

Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded

Exclusions & screening

Exclusions Screening list

Checks a prime runs before teaming: SAM.gov exclusions (debarment and suspension) and the government's Consolidated Screening List for export and sanctions lists.

SAM.gov exclusions

Not yet checked against SAM.gov exclusions.

Search exclusions on SAM.gov (opens in a new tab)

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded

Consolidated Screening List

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.

Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026

GSA CALC+ rate benchmark

Learn more

Hourly ceiling rates this company was awarded on GSA contracts, compared with the market for similar labor categories. Ceiling rates are the most an agency can be charged, not prices paid.

No GSA CALC+ rates on record

Companies with a GSA Multiple Award Schedule contract appear here after CALC+ publishes their awarded labor rates.

See GSA MAS holders

Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded

NAICS, PSC & socio-economic status

Learn more

Industry codes and small-business programs reported in SAM.gov.

NAICS codes

325412Pharmaceutical Preparation ManufacturingPrimary

SAM.gov does not report this entity as small under any listed NAICS code.

Socio-economic status

No socio-economic certifications reported in SAM.gov.

Product & service codes (PSC)

No PSC codes reported.

Teaming preferences

Learn more

This company has not published teaming preferences.

SAM.gov teaming eligibility: Eligible to be proposed as a team member: active SAM.gov registration and no exclusion.

Business development contact

No BD contact published

Contact details appear once the company claims this profile.

Is this your company? Claim it

Corporate hierarchy

Affiliation & size

Immediate parent and highest-level owner as reported in SAM.gov.

No parent entity reported in SAM.gov.

SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.

Data sources & provenance

Who stands behind each fact on this page, and how to correct it.

SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.

Corrections

Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)

Machine-readable: capability.md schema.org JSON-LD embedded in this page.

Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.

Teaming

Ready to team with PROGENICS PHARMACEUTICALS INC?

Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.

Claim this profile Capability statement (.md)